JCI Insight 'Under Review': What Each Status Means and When to Expect a Decision

Before the paper reaches external reviewers, a JCI Insight senior editor evaluates whether the clinical-research mechanism and disease relevance warrant JCI Insight's editorial slots. About 40 to 50 percent of submissions are desk-rejected at this stage within 1 to 2 weeks.

A desk rejection most often means the working-scientist senior editor concluded that the work would fit better at a sister JCI journal (the JCI flagship for top-tier mechanistic clinical investigation, JCI Insight for broader-scope mechanistic clinical) or that the JCI Insight clinical-research mechanism bar is not met. The working-scientist editor model means desk decisions take a few days longer than the full-time professional editor model at Nature or Cell.

The JCI Insight editorial office confirms files are complete: manuscript with figures embedded, Supporting Information with clinical-research data, JCI template formatting, CONSORT checklist for clinical-trial components, reporting checklists where applicable (STROBE for observational studies, ARRIVE for animal work), cover letter directed to the editor naming clinical-research mechanism and disease relevance, conflict-of-interest declarations, ethics-statement documentation, IRB approvals, and data-availability statement.

The working-scientist senior editor reads the paper and evaluates clinical-research mechanism, disease relevance, and JCI Insight subspecialty routing. Working-scientist editors are running their own labs and fitting editorial decisions into weeks that are already full, which adds a few days to the triage timeline compared to full-time professional editor journals.

In parallel with the senior editor's primary read, ambiguous-fit papers are discussed across the JCI editorial team where peer senior editors weigh in on whether the paper would fit better at JCI Insight flagship or at the JCI parent journal. This editorial discussion runs alongside the desk-screen and adds 3 to 7 days to the timeline that is invisible to the author in the portal.

JCI Insight senior editors typically invite 6 to 8 potential reviewers to get 2 to 3 acceptances. The recruitment window can take 2 to 4 weeks because reviewer recruitment is where JCI loses more time than any other stage. The journal needs reviewers who understand both the mechanistic approach and the specific disease area, a narrow intersection.

Once 2 to 3 reviewers agree to review (out of 6 to 8 initially invited), the typical JCI Insight peer-review cycle lasts 4 to 8 weeks per reviewer, contributing to the 6 to 10 week first-decision window. Reviewers are asked to evaluate clinical-research mechanism, disease relevance, methodology rigor, and reproducibility. Reviewer reports for JCI Insight tend to be thorough; 2000 to 4000 word reports are typical given the mechanism-and-disease-area complexity.

After reports return, the senior editor synthesizes them. Total submission-to-acceptance commonly runs 4 to 8 months for successful papers, including revision rounds.

• Rejection within 1 to 7 days: Administrative issue or immediate scope mismatch.

• Rejection within 7 to 14 days: Working-scientist senior editor desk rejection per the 1 to 2 week target.

• Still Under Review after 2 weeks: Strong signal. Paper passed the JCI Insight senior editor desk screen.

• Still Under Review after 10 weeks: Reviewer-recruitment difficulty (6 to 8 potential reviewers invited to get 2 to 3 acceptances) or reviewer-report delay. A polite inquiry via the JCI Insight submission portal is appropriate.

• Status changes to "Decision Pending": Reports are in; expect a decision within 1 to 2 weeks.

This is the most common anxiety we hear from JCI Insight authors during the active editorial window. The honest answer: no, 6 weeks at Under Review puts you in the normal middle of JCI Insight's 6 to 10 week first-decision distribution. Reports may already be in editorial synthesis with the senior editor preparing the recommendation.

Most reviewer-driven delays come from reviewer-recruitment difficulty (the mechanism-and-disease-area intersection is narrow, so editors invite 6 to 8 potential reviewers to get 2 to 3 acceptances) rather than slow reviews.

If the portal still says Under Review at the 10-week mark, the most likely explanation is that the senior editor is still recruiting reviewers from the original 6 to 8 invitation list, or that one of the assigned reviewers asked for an extension. This is normal practice at JCI Insight.

During the 6-to-10-week window, the useful distinction is whether you have new information the editor needs. A short portal message is reasonable for an ethics update, corrected data-availability statement, related-paper disclosure, preprint status change, or a material authorship or conflict-of-interest correction. A general timeline request is better held until week 10 because reviewer recruitment in the mechanism-plus-disease niche is the usual cause of silence.

If your JCI Insight paper is rejected after review, the natural cascade depends on what the reviewers and senior editor cited:

JCI flagship is the natural JCI cascade for top-tier mechanistic clinical investigation papers.

Cell Reports Medicine is the external Cell Press clinical-translation cascade. Cell Press uses Editorial Manager at Editorial Manager submission portal; editorial contact crmed@cell.com.

Science Translational Medicine is the external AAAS clinical-translation cascade. AAAS uses the Centralized Tracking System at Science family CTS submission portal; editorial contact stm@aaas.org.

Nature Medicine is the external Springer Nature top-tier clinical cascade. The Nature Medicine Manuscript Tracking System at mts-nmed.nature.com handles submission; nmed@nature.com handles publisher-level inquiries.

Nature Communications is the external Springer Nature broader cascade.

eLife is a cascade option for clinical-research work under the Reviewed Preprint model.

JCI asks reviewers at JCI Insight to evaluate four things specifically. The table below maps each to actionable preparation.

In our pre-submission work with JCI Insight-targeted manuscripts, three named patterns generate the most consistent reviewer concerns and the most common reasons papers miss the editorial bar or fail the desk screen.

Mechanism-without-disease-relevance framing flagged at senior editor screen. When the work presents clinical-research mechanism without connection to a specific disease area, JCI Insight desk rejection within 1 to 2 weeks is common. The strongest manuscripts frame both the mechanistic approach and the specific disease area explicitly.

Check your mechanism and disease-relevance framing →

Reviewer-recruitment difficulty surfaces as elongated timeline. When the mechanism-and-disease-area intersection is particularly narrow, the senior editor may need to invite well beyond the typical 6 to 8 potential reviewers to get 2 to 3 acceptances. The strongest submissions help by suggesting potential reviewers who span the intersection in the cover letter.

Check your reviewer-routing package →

JCI flagship cascade offers from senior editor. When the senior editor concludes the work is rigorous and the mechanism contribution is top-tier, the JCI flagship is the natural cascade for a higher-priority review. JCI editors take these transfers seriously.

Check your JCI versus JCI Insight route →

We have reviewed 50+ manuscripts targeting JCI Insight, JCI, Nature Medicine, Cell Reports Medicine, and Science Translational Medicine. The recurring JCI Insight pattern is not simply "mechanism is weak." It is that the disease relevance, model choice, patient-sample logic, or translational endpoint is not visible early enough for a working-scientist senior editor to route the paper confidently. A paper can have strong biology and still feel mispositioned if the first page reads like a disease-adjacent mechanism study rather than mechanistic clinical investigation.

In the 100-manuscript Manusights sample across translational medicine and clinical-mechanism targets, Manusights internal analysis identifies five recurring preventable risks: mechanism and disease relevance separated into different sections, incomplete explanation of human-sample provenance, animal-model claims that overreach the model, data-availability statements that do not match the figures, and reviewer suggestions that cover the method but not the disease area. This is an internal Manusights review sample, not JCI outcome data, so it is best used as a risk map for preventable author-side issues.

Source limitation: official guidance explains JCI Insight author rules, submission package requirements, and publication ethics, but it does not show private senior-editor notes, reviewer-invitation history, or the reason a specific manuscript is still in the portal. That is why this page separates public status interpretation from manuscript-specific readiness signals.

The most useful JCI Insight preparation is often a routing audit rather than a line edit. We check whether the title, abstract, first figure, and cover letter all name the same mechanism and the same disease consequence; whether the controls support the causal claim; and whether the methods let a reviewer reproduce the central clinical-research inference. Manusights does not train AI models on customer manuscripts; we do not train on private author files.

Eligible paid manuscript reviews include the 60-day money-back guarantee. That matters for JCI Insight authors because unpublished patient-derived data, image files, and mechanistic claims should be reviewed privately.

This page was created from JCI's public JCI Insight author information center at Insight author instructions, JCI editorial documentation (1 to 2 week desk decisions, 6 to 10 week first decisions, working-scientist editor model with editors running their own labs, reviewer-recruitment difficulty requiring 6 to 8 potential reviewer invitations to get 2 to 3 acceptances), and Manusights pre-submission review experience with JCI Insight-targeted manuscripts.

For the JCI clinical-research landscape beyond JCI Insight, see JCI flagship (top-tier mechanistic clinical investigation) and external clinical-research alternatives (Cell Reports Medicine, Science Translational Medicine, Nature Medicine, Nature Communications, eLife). The choice across these titles depends on whether the central contribution is broader-scope mechanistic clinical (JCI Insight), top-tier mechanistic (JCI), Cell Press clinical-translation (Cell Reports Medicine), AAAS clinical-translation (Science Translational Medicine), top-tier Nature medical (Nature Medicine), broader Nature Portfolio (Nature Communications), or Reviewed Preprint (eLife).

Reviewers at JCI Insight typically draw from 2 to 3 mechanistic-and-disease-area subspecialty experts (selected from 6 to 8 potential reviewers initially invited) under the JCI single-blind model. Editors screen and triage manuscripts before any reviewer sees them, and preparing a response template that addresses both mechanism and disease relevance accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the JCI Insight mechanistic-clinical-research bar before submission, our JCI Insight pre-submission diagnostic flags the framing and methodology weaknesses most likely to surface in reviewer reports.